This study, published in the Journal of Pharmacy & Pharmacognosy Research, investigates the prevalence and predictors of drug-drug interactions (DDIs) in an outpatient setting in Southern Vietnam. By analyzing over 1,200 prescriptions, the researchers found that more than one-third of patients were at risk of clinically significant interactions, primarily driven by polypharmacy and chronic conditions like hypertension and diabetes.
TL;DR
Over 36% of outpatient prescriptions at a city-affiliated healthcare center in Vietnam contain at least one clinically significant drug interaction, with polypharmacy and hypertension being the strongest predictors of risk. The study underscores an urgent need for computerized screening tools and clinical pharmacist intervention to prevent adverse drug events in primary care.
What Problem Does This Paper Address?
Drug-drug interactions (DDIs) occur when the effect of one medication is altered by another, often leading to reduced efficacy or increased toxicity. These interactions are a major public health burden, contributing to nearly 46% of preventable hospital admissions globally.
In Vietnam, while DDI prevalence in inpatient settings is well-documented (ranging from 34% to 85%), there is a significant data gap regarding outpatient care at city-affiliated centers. As the population ages and the prevalence of chronic "lifestyle" diseases grows, patients are increasingly prescribed multiple medications (polypharmacy), creating a fertile ground for dangerous drug combinations. This paper seeks to quantify that risk and identify which patient profiles are most vulnerable.
Methods
The researchers conducted a cross-sectional descriptive study at a Level III city-affiliated healthcare center between January and June 2023.
- Sampling: They used systematic random sampling to select 1,203 outpatient prescriptions that contained at least two medications.
- DDI Screening: Each prescription was cross-referenced against two major international databases: the Drug Interactions Checker (Drugs.com) and the Medscape Interactions Checker.
- Classification: Interactions were categorized by severity (Contraindicated, Severe, Moderate, or Mild). "Clinically significant" interactions were defined as those requiring medical intervention or dose adjustments.
- Statistical Analysis: The team employed univariate and multivariate logistic regression (using SPSS v22) to determine the Odds Ratio (OR) for various risk factors, such as age, number of diseases, and specific comorbidities.
Datasets
The primary dataset consisted of 1,203 anonymized outpatient prescriptions collected directly from the center's Department of Medical Examination. To evaluate these, the authors relied on two established clinical benchmarks:
- Drug Interactions Checker (Drugsite Trust)
- Medscape Interactions Checker (WebMD)
Key Insights and Ideas
- The Polypharmacy Threshold: The risk of a DDI jumps significantly once a patient is prescribed five or more medications (OR = 3.305). This confirms that the sheer volume of drugs is a primary driver of risk, regardless of the specific drugs involved.
- Comorbidity as a Red Flag: Patients with hypertension were over seven times more likely (OR = 7.142) to experience a DDI. This is likely due to the complex multi-drug regimens required for blood pressure management, which often overlap with treatments for diabetes or dyslipidemia.
- Common but Risky Pairings: The most frequent interaction involved Amlodipine and Metformin (9.9%). While common, this combination can lead to pharmacokinetic antagonism, where the blood pressure medication inadvertently reduces the glucose-lowering effect of the diabetes medication.
- The Statin/Calcium Channel Blocker Conflict: A notable severe interaction found was Amlodipine combined with Simvastatin. This pairing increases the risk of myopathy and rhabdomyolysis (muscle breakdown), leading the authors to highlight the importance of FDA-recommended dose limits for these specific combinations.
Key Results
- Prevalence: 36.7% of prescriptions had at least one clinically significant DDI.
- Severity: 3% of prescriptions contained "severe" interactions, while 35.1% contained "moderate" ones.
- Top Predictors (Multivariate Analysis):
- Hypertension: OR 7.142 (95% CI: 4.658–10.950)
- Polypharmacy ($\ge 5$ drugs): OR 3.305 (95% CI: 2.320–4.708)
- Non-insulin-dependent diabetes: OR 2.447 (95% CI: 1.817–3.295)
- Dyslipidemia: OR 2.242 (95% CI: 1.665–3.020)
- Demographics: The average patient was approximately 59 years old, and the majority (61.6%) were female.
Limitations and Future Work
The authors acknowledge several limitations:
- Geographic Scope: The study was limited to a single center in An Giang Province, which may not reflect prescribing patterns across all of Vietnam.
- Database Gaps: International databases like Medscape may not include local or traditional Vietnamese medicines that could interact with Western pharmaceuticals.
- Inconsistency: Differences in how various databases classify "severity" can lead to inconsistencies in defining the degree of interaction.
Future Work: The authors advocate for the implementation of computerized alert systems with intelligent screening software in Vietnamese hospitals. They also emphasize the need for clinical pharmacists to play a more active role in reviewing prescriptions before they reach the patient.
Summary updated